Insider · CIK 0001449008
Harlan Waksal
Files at LYRA (Lyra Therapeutics, Inc.), FRNM (Freenome, Inc.). First filing -, latest -.
Harlan Waksal files SEC Form 4 as chair and director at LYRA (Lyra Therapeutics, Inc.), and also at FRNM (Freenome, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Harlan Waksal has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 25, 2025 | LYRA Lyra Therapeutics, Inc. | 145,370 0.22% of outstanding | $15k | Apr 25, 2025 | none |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | FRNM Freenome, Inc. | CConversion Common Stock | +30,000 | - | - | 30,000 | Jul 29, 2026 |
| Jul 20, 2026 | FRNM Freenome, Inc. | CConversion Class B Ordinary Sharesderivative | -30,000 | - | - | 0 | Jul 29, 2026 |
| Dec 9, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Performance-based Restricted Stock Unitsderivative | -128,333 | $0.00 | $0 | 0 | Dec 11, 2024 |
Questions about Harlan Waksal
Answered from the filings on this page, as of the latest one.
Is Harlan Waksal buying or selling?
Harlan Waksal has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Harlan Waksal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Harlan Waksal has 0.
Where does Harlan Waksal file Form 4?
Harlan Waksal has filed Form 4 at LYRA (Lyra Therapeutics, Inc.) as Executive Chair; FRNM (Freenome, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.